Definium Therapeutics annual shares outstanding
2021
2022
2023
2024
2025
Definium Therapeutics Shares Outstanding History (DFTX)
Definium Therapeutics reported 98.8M shares outstanding at the end of fiscal 2025.
View full Definium Therapeutics company overviewDefinium Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 98.8M | 23.7M | +31.52% |
| 2024 | 2024-12-31 | 75.1M | 34.0M | +82.72% |
| 2023 | 2023-12-31 | 41.1M | 3.1M | +8.22% |
| 2022 | 2022-12-31 | 38.0M | 9.9M | +35.03% |
| 2021 | 2021-12-31 | 28.1M | — | — |
Definium Therapeutics quarterly shares outstanding
Q4.21
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 134.4M | 58.6M | +77.26% |
| Q1 2026 | 2026-03-31 | 104.0M | 28.5M | +37.79% |
| Q4 2025 | 2025-12-31 | 98.8M | 23.7M | +31.52% |
| Q3 2025 | 2025-09-30 | 76.8M | −4.8M | −5.90% |
| Q2 2025 | 2025-06-30 | 75.8M | 3.7M | +5.17% |
| Q1 2025 | 2025-03-31 | 75.5M | 4.3M | +6.11% |
| Q4 2024 | 2024-12-31 | 75.1M | 34.0M | +82.72% |
| Q3 2024 | 2024-09-30 | 81.6M | 41.5M | +103.49% |
| Q2 2024 | 2024-06-30 | 72.1M | 33.3M | +85.73% |
| Q1 2024 | 2024-03-31 | 71.2M | 32.9M | +85.85% |
| Q4 2023 | 2023-12-31 | 41.1M | 3.1M | +8.22% |
| Q3 2023 | 2023-09-30 | 40.1M | 2.6M | +6.80% |
| Q2 2023 | 2023-06-30 | 38.8M | −387.9M | −90.91% |
| Q1 2023 | 2023-03-31 | 38.3M | 10.2M | +36.14% |
| Q4 2022 | 2022-12-31 | 38.0M | — | — |
| Q3 2022 | 2022-09-30 | 37.5M | — | — |
| Q2 2022 | 2022-06-30 | 426.7M | — | — |
| Q4 2021 | 2021-12-31 | 28.1M | — | — |
Definium Therapeutics shares outstanding trends
Across the available reported history, Definium Therapeutics's shares outstanding moved from 75.1M to 98.8M, a change of 23.7M. The latest reported quarter, Q2 2026, shows 134.4M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Definium Therapeutics filings at SEC.gov ↗